Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report Intel FAQ API Sign In →
31 /100
MEDIUM RISK
Score updated Jul 28, 2026

BCYC — Bicycle Therapeutics plc Dilution Risk Tracker

Track BCYC dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track BCYC — Get alerts when the score changes →

As of July 28, 2026, Bicycle Therapeutics plc (BCYC) has a DilutionWatch DilutionScore of 31/100, rated MEDIUM dilution risk. Bicycle Therapeutics plc has a market capitalization of $327.41M, 30.04M shares outstanding, 100 institutional holders tracked. Key dilution vectors include 92.9K outstanding warrants, approximately 25 months of cash runway.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

Score Breakdown

📋 Offering Ability
40
💰 Cash Runway
10
📊 Float Risk
10
⚠️ Warrant Exposure
15
🔄Convertible Debt

Dilution Forecast

☀️
Clear
No significant dilution signals
0%
No significant dilution signals detected for BCYC.
🔔 Track BCYC — Get forecast alerts →

Market Data

Market Cap$327.41M
Shares Outstanding30.04M
FloatN/A
Cash$559.47M
Debt$30.91M
Short InterestN/A

Institutional Holdings

QoQ: ↑ 0.9% shares (2026Q1 vs prior)
100 institutional holders · 40.56M shares
#1 BAKER BROS. ADVISORS LP 10.89M shares
#2 FCPM III SERVICES B.V. 3.47M shares
#3 ARMISTICE CAPITAL, LLC 3.40M shares
+ 17 more holders Sign up free to view →

Short Interest

Short Interest2.98M
Days to Cover7.7
% of FloatN/A
FINRA data as of Jul 15, 2026

Recent SEC Activity

xbrl XBRL WARRANT 2026-07-07
xbrl XBRL CONVERTIBLE 2019-12-31
4 INSIDER TRANSACTION 2026-04-06
4 INSIDER TRANSACTION 2026-04-06
4 INSIDER TRANSACTION 2026-04-06
Full SEC filing analysis available with free account

Recent News

No recent news

What This Means for BCYC Shareholders

Bicycle Therapeutics plc (BCYC) has a DilutionScore of 31/100, rated Medium dilution risk. This tier indicates some dilution exposure — often an older shelf registration with remaining capacity, warrants not yet exercised, or a cash position that will require monitoring over the next several quarters. Score as of July 28, 2026.

DilutionWatch's EDGAR monitoring for BCYC shows no major active dilution programs at this time. The primary risk categories — shelf registration capacity, ATM programs, warrant overhang, and cash runway — are each within normal ranges for a company of this profile. This can change quickly if a new S-3 or Form S-1 is filed.

DilutionWatch tracks over 25 SEC filing types for BCYC in real-time, scanning EDGAR every 60 seconds. The DilutionWatch shows real-time score changes for BCYC alongside comparable medium-risk stocks. Not financial advice — this analysis is for informational purposes only.

Understanding BCYC's Dilution Risk Factors

Primary Risk Drivers

The most significant dilution risks for Bicycle Therapeutics plc stem from Offering Ability and Convertible Note Risk. Offering Ability scores at a moderate level, indicating that the company has the capacity to raise capital through equity offerings, which inherently increases share count. Convertible Note Risk is also elevated, suggesting that convertible debt obligations could convert into common shares, further diluting existing shareholders. These factors are particularly concerning because they represent potential pathways for new equity issuance without direct shareholder approval in many cases.

Factors Currently Not a Concern

Float Risk and Warrant Exposure are currently low, signaling minimal risk from large-scale stock issuance through public trading or warrant exercises. Float Risk remains manageable, but any significant increase in publicly traded shares could raise this score. Warrant Exposure is also low, though an increase in outstanding warrants would elevate this metric. Additionally, Cash Runway is well above average, meaning the company has a solid buffer against immediate liquidity pressures that might otherwise trigger dilutive financing.

SEC Filings to Watch

Several SEC filings are critical for monitoring BCYC’s dilution risk. An S-3 registration statement could signal an upcoming equity offering, directly increasing share count. A 424B5 filing often accompanies new equity offerings and should be reviewed for details on pricing and issuance terms. An 8-K Item 1.01 event might indicate a material change in capital structure or financing activities. A 10-Q filing may reveal updated financials that could suggest increased reliance on dilutive financing, particularly if cash reserves decline significantly.

How Dilution Happens

The process begins with the company issuing new shares through offerings or converting debt into equity. When Offering Ability is high, it means the firm can issue more stock without significant barriers. If convertible notes convert, existing holders see their ownership percentage decrease as total shares increase. Each of these mechanisms directly increases the number of outstanding shares, reducing earnings per share and diluting the value of each existing stake.

What Would Make This Worse

A worsening scenario would involve a combination of events: a large convertible note conversion, an upcoming equity offering, and a decline in cash reserves that forces further financing. If these factors align, the company’s ability to raise capital may become more urgent, leading to increased issuance of new shares. Additionally, if warrants are exercised en masse or if there is a sudden drop in cash runway, it could trigger a cascade of dilutive actions that significantly impact existing shareholders.

Key Insight

While the current risk profile shows manageable levels of dilution exposure, vigilance around capital structure changes and financing activities is essential for protecting shareholder value.

How to Monitor BCYC for Dilution Risk

What This Risk Level Means

For a small-cap operating company like Bicycle Therapeutics plc (BCYC), a medium dilution risk level indicates that the firm has some exposure to potential dilution through equity issuance, but is not currently in immediate danger. The company's size and stage of development mean it likely relies on capital markets for growth funding, increasing the probability of future equity offerings. However, the current risk score suggests that while dilution is possible, it is not yet at a critical or imminent level. This makes ongoing monitoring essential, especially as the company progresses through its lifecycle.

What Typically Happens Next

Companies at this profile often proceed with capital-raising activities such as shelf registrations, ATM programs, or convertible note offerings to fund operations and growth. These mechanisms allow firms to raise capital on demand, which can lead to increased equity issuance over time. For a small-cap company like BCYC, the use of convertible notes or warrants may be common, as these instruments are often used to attract investors without immediate dilution concerns. Monitoring for such activities is key, particularly in the context of upcoming funding rounds or strategic partnerships.

Monitoring Playbook

To track BCYC’s dilution risk effectively, use DilutionWatch to monitor score changes and key events. Set alerts for any change in DilutionScore above 40/100, as this would signal a significant increase in risk. Check the company’s filings monthly for new offerings or convertible note activity. Additionally, monitor Shelf & ATM Monitor to detect any shelf registration filings that may precede future dilution events.

Early Warning Signals

Several indicators can signal worsening dilution risk: a sudden increase in Offering Ability or Convertible Note Risk scores, the filing of a shelf registration, or the announcement of a convertible note offering. Any of these signals suggests that the company is actively preparing for equity issuance, which could lead to higher dilution in the future.

What a Positive Resolution Looks Like

A positive resolution would involve a capital raise that reduces reliance on future equity issuance or a strategic reduction in outstanding warrants and convertible notes. If BCYC were to pay down debt or see significant warrant expirations without new issuances, the dilution risk profile could improve. Additionally, securing long-term partnerships or funding with non-dilutive terms would help lower the risk score.

Watch For

Any changes in Offering Ability or Convertible Note Risk scores above 40/100, as these are strong indicators of increasing dilution risk.

Full SEC filing analysis available with free account  →
Track BCYC Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking BCYC — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for BCYC
BCYC FDA Catalyst Timeline & Biotech Grade — BiotechSignsBCYC Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.